Suppression of primary and disseminated murine tumor growth with eIF5A1 gene therapy

Gene Therapy and Molecular Biology

Volumn 12, Issue 2, 2008, Pages 207-218

  Jin, Songmu ^a   Taylor, Catherine A ^a   Liu, Zhongda ^a   Sun, Zhong ^a   Ye, Bin ^a   Thompson, John E ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Adenovirus; Apoptosis; DOTAP; Eukaryotic translation initiation factor 5A (eIF5A); Gene therapy; Lung cancer; Melanoma

Indexed keywords

ADENOVIRIDAE; ANIMALIA; EUKARYOTA; MURINAE; MUS;

EID: 77649135449     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19, 3622-3634.
2. Bessis N, GarciaCozar FJ and Boissier MC (2004) Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11, S10-S17.
3. Bragonzi A, Boletta A, Biffi A, Muggia A, Sersale G, Cheng SH, Bordignon C, Assael BM, Conese M (1999) Comparison between cationic polymers and lipids in mediating systemic gene delivery to the lungs. Gene Ther 6, 1995-2004.
4. Bragonzi A, Dina G, Villa A, Calori G, Biffi A, Bordignon C, Assael BM, Conese M (2000) Biodistribution and transgene expression with nonviral cationic vector/DNA complexes in the lungs. Gene Ther 7, 1753-1760.
5. Caraglia M, Marra M, Giuberti G, D'Alessandro AM, Baldi A, Tassone P, Venuta S, Tagliaferri P, Abbruzzese A (2003) The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. J Biochem 133, 757-765.
6. Chen G, Gharib TG, Thomas DG, Huang CC, Misek DE, Kuick RD, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG (2003) Proteomic analysis of eIF-5A in lung adenocarcinomas. Proteomics 3, 496-504.
7. Chen ZP and Chen KY (1997) Marked elevation of hypusine formation activity on eukaryotic initiation factor 5A in v-HA-RAS transformed mouse NIH3T3 cells. Cancer Lett 272, 15865-15871.
8. Clement PM, Henderson CA, Jenkins ZA, Smit-McBride Z, Wolff EC, Hershey JW, Park MH, Johansson HE (2003) Identification and characterization of eukaryotic initiation factor 5A-2. Eur J Biochem 270, 4254-4263.
9. Clement PM, Johansson HE, Wolff EC and Park MH (2006) Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J 273, 1102-1114.
10. Cracchiolo BM, Heller DS, Clement DMJ, Wolff EC, Park MH and Hanauske-Abel HH (2004) Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva. Gynecol Oncol 94, 217-222.
11. Guan XY, Fung JM, Ma NF, Lau SH, Tai LS, Xie D, Zhang Y, Hu L, Wu QL, Fang Y, Sham JS (2004) Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res 64, 4197-4200.
12. Guan XY, Sham, JS, Tang TC, Fang Y, Huo KK and Yang JM (2001) Isolation of a Novel Candidate Oncogene within a Frequently Amplified Region at 3q26 in Ovarian Cancer. Cancer Res 61, 3806-3809.
13. Hanauske-Abel HM, Slowinska B, Zagulska S, Wilson RC, Staiano-Coico L, Hanauske AR, McCaffrey T, Szabo P (1995) Detection of a sub-set of polysomal mRNAs associated with modulation of hypusine formation at the G1-S boundary. Proposal of a role for eIF-5A in onset of DNA replication. FEBS Lett 366, 92-98.
14. Hodges BL, Taylor KM, Joseph MF, Bourgeois SA and Scheule RK (2004) Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 10, 269-278.
15. Jasiulionis MG, Luchessi AD, Moreira AG, Souza PP, Suenaga AP, Correa M, Costa CA, Curi R, Costa-Neto CM (2007) Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth. Cell Biochem Funct 25, 109-114.
16. Jenkins ZA, Haag PG and Johansson HE (2001) Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics 71, 101-109.
17. Jin BF, He K, Wang HX, Wang J, Zhou T, Lan Y, Hu MR, Wei KH, Yang SC, Shen BF, Zhang XM (2003) Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A. Oncogene 22, 4819-4830.
18. Kang, HA and Hershey, JW (1994) Effect of initiation factor eIF-5A depletion on protein synthesis and proliferation of Saccharomyces cerevisiae. J Biol Chem 269, 3934-3940.
19. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
20. Li AL, Li HY, Jin BF, Ye QN, Zhou T, Yu XD, Pan X, Man JH, He K, Yu M, Hu MR, Wang J, Yang SC, Shen BF, Zhang XM (2004) A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem 279, 49251-49258.
21. Li S and Huang L (1997) In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 4, 891-900.
22. Li S, Wu SP, Whitmore M, Loeffert EJ, Wang L, Watkins SC, Pitt BR, Huang L (1999) Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol 276, L796 -L804.
23. Liu YP, Nemeroff M, Yan YP and Chen KY (1997) Interaction of eukaryotic initiation factor 5A with the human immunodeficiency virus type 1 Rev response element RNA and U6 snRNA requires deoxyhypusine or hypusine modification. Biol Signals 6, 166-174.
24. Marchet A, Mocellin S, Belluco C, Ambrosi A, DeMarchi F, Mammano E, Digito M, Leon A, D'Arrigo A, Lise M, Nitti D (2007) Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol 14, 1058-1064.
25. Park JH, Aravind L, Wolff EC, Kaevel J, Kim YS and Park MH (2006) Molecular cloning, expression, and structural prediction of deoxyhypusine hydroxylase: a HEAT-repeat-containing metalloenzyme. Proc Natl Acad Sci U S A 103, 51-56.
26. Park MH, Wolff EC and Folk JE (1993) Is hypusine essential for eukaryotic cell proliferation? Trends Biochem Sci 18, 475-479
27. Park MH, Wolff EC, Lee YB and Folk JE (1994) Antiproliferative effects of inhibitors of deoxyhypusine synthase: Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. J Biol Chem 269, 27827-27832.
28. Peng Z (2005) Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers. Hum Gene Ther 16, 1013-1024.
29. Rahman-Roblick R, Roblick UJ, Hellman U, Conrotto P, Liu T, Becker S, Hirschberg D, Jörnvall H, Auer G, Wiman KG (2007) p53 targets identified by protein expression profiling. Proc Natl Acad Sci U S A 104, 5401-5406.
30. Ramaswamy S, Ross KN, Lander ES and Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33, 49-54.
31. Reyes-Sandoval A and Ertl HC (2004) CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol Ther 9, 249-261.
32. Schnier J, Schwelberger HG, Smit-McBride Z, Kang HA and Hershey JW (1991) Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiaie. Mol Cell Biol 11, 3105-3114.
33. Schrader R, Young C, Kozian D, Hoffman R and Lottspeich F (2006) Temperature-sensitive eIF5A mutant accumulates transcripts targeted to the nonsense-mediated decay pathway. J Biol Chem 281, 35336-35346.
34. Song YK, Liu F, Chu SY and Liu DX (1997) Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum Gene Ther 8, 1585-1594.
35. Sörenson S, Glimelius B, Nygren P, SBU-group, Swedish Council of Technology Assessment in Health Care (2001) A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol 40, 327-339.
36. Tan Y, Li S, Pitt BR and Huang L (1999) The Inhibitory Role of CpG Immunostimulatory Motifs in Cationic Lipid Vector-Mediated Transgene Expression in Vivo. Hum Gene Ther 10, 2153-2161.
37. Taylor CA, Senchyna M, Flanagan J, Joyce EM, Cliche DO, Boone AN, Culp-Stewart S, Thompson JE (2004) Role of eIF5A in TNF-alpha-mediated apoptosis of lamina cribrosa cells. Invest Ophthalmol Vis Sci 45, 3568-3576.
38. Taylor CA, Sun Z, Cliche DO, Ming H, Eshaque B, Jin S, Hopkins MT, Thai B, Thompson JE (2007) Eukaryotic translation initiation factor 5A induces apoptosis in colon cancer cells and associates with the nucleus in response to tumour necrosis factor alpha signalling. Exp Cell Res 313, 437-449.
39. Tome M, Fiser S, Payne C and Gerner E (1997) Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. Biochem J 328, 847-854.
40. Tousignant JD, Gates AL, Ingram LA, Johnson CL, Nietupski JB, Cheng SH, Eastman SJ, Scheule RK (2000) Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 11, 2493-2513.
41. Wolff EC, Park MH and Folk JE (1990) Cleavage of spermidine as the first step in deoxyhypusine synthesis. The role of NAD. J Biol Chem 265, 4793-4799.
42. Xie D, Ma NF, Pan ZZ, Wu HX, Liu YD, Wu GQ, Kung HF, Guan XY (2008) Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma. Hum Pathol 39, 80-86.
43. Xu A, Jao DL and Chen KY (2004) Identification of mRNA that binds to eukaryotic initiation factor 5A by affinity copurification and differential display. Biochem J 384, 585-590.
44. Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK, Cheng SH (2002) CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther 5, 731-738.
45. Yew NS, Zhao H, Wu IH, Song A, Tousignant JD, Przybylska M, Cheng SH (2000) Reduced Inflammatory Response to Plasmid DNA Vectors by Elimination and Inhibition of Immunostimulatory CpG Motifs. Mol Ther 1, 255-262.
46. Yew NS, Wang KX, Przybylska M, Bagley RG, Stedman M, Marshall J, Scheule RK, Cheng SH (1999) Contribution of Plasmid DNA to Inflammation in the Lung after Administration of Cationic Lipid:pDNA Complexes. Hum Gene Ther 10, 223-234.
47. Zanelli CF, Maragno AL, Gregio AP, Komili S, Pandolfi JR, Mestriner CA, Lustri WR, Valentini SR (2006) eIF5A binds to the translational machinery components and affects translation in yeast. Biochem Biophys Res Commun 348, 1358-1366.
48. Zhao H, Hemmi H, Akira S, Cheng SH, Sheule RK and Yew NS (2004) Contribution of toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther 9, 241-248.
49. Zuk D and Jacobson A (1998) A single amino acid substitution in yeast eIF-5A results in mRNA stabilization. EMBO J 17, 2914-2925.